CVE:SBM

Sirona Biochem Competitors

C$0.39
+0.05 (+13.04 %)
(As of 04/20/2021 12:10 PM ET)
Add
Compare
Today's Range
C$0.31
Now: C$0.39
C$0.39
50-Day Range
C$0.33
MA: C$0.41
C$0.56
52-Week Range
C$0.19
Now: C$0.39
C$0.56
Volume88,315 shs
Average Volume135,487 shs
Market CapitalizationC$88.79 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Sirona Biochem (CVE:SBM) Vs. IMV, RVX, FRX, ATE, ONC, and IPA

Should you be buying SBM stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Sirona Biochem, including IMV (IMV), Resverlogix (RVX), Fennec Pharmaceuticals (FRX), Antibe Therapeutics (ATE), Oncolytics Biotech (ONC), and ImmunoPrecise Antibodies (IPA).

Sirona Biochem (CVE:SBM) and IMV (TSE:IMV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.

Profitability

This table compares Sirona Biochem and IMV's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sirona BiochemN/AN/AN/A
IMVN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Sirona Biochem and IMV, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sirona Biochem0000N/A
IMV04002.00

IMV has a consensus price target of C$5.08, suggesting a potential upside of 49.51%. Given IMV's higher probable upside, analysts clearly believe IMV is more favorable than Sirona Biochem.

Valuation & Earnings

This table compares Sirona Biochem and IMV's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sirona BiochemC$123,870.00716.78C$-2,959,580.00C($0.01)-30.00
IMVC$3,000.0076,739.13C$-39,136,958.00C($0.58)-5.88

Sirona Biochem has higher revenue and earnings than IMV. Sirona Biochem is trading at a lower price-to-earnings ratio than IMV, indicating that it is currently the more affordable of the two stocks.

Sirona Biochem (CVE:SBM) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.

Profitability

This table compares Sirona Biochem and Resverlogix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sirona BiochemN/AN/AN/A
ResverlogixN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Sirona Biochem and Resverlogix, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sirona Biochem0000N/A
Resverlogix0000N/A

Valuation & Earnings

This table compares Sirona Biochem and Resverlogix's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sirona BiochemC$123,870.00716.78C$-2,959,580.00C($0.01)-30.00
ResverlogixN/AN/AN/AC$0.0163.57

Resverlogix has lower revenue, but higher earnings than Sirona Biochem. Sirona Biochem is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

Summary

Resverlogix beats Sirona Biochem on 2 of the 3 factors compared between the two stocks.

Sirona Biochem (CVE:SBM) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Sirona Biochem and Fennec Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sirona BiochemN/AN/AN/A
Fennec PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Sirona Biochem and Fennec Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sirona Biochem0000N/A
Fennec Pharmaceuticals00203.00

Valuation and Earnings

This table compares Sirona Biochem and Fennec Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sirona BiochemC$123,870.00716.78C$-2,959,580.00C($0.01)-30.00
Fennec PharmaceuticalsC$170,000.001,153.31C$-24,858,868.00C($0.96)-7.89

Sirona Biochem has higher earnings, but lower revenue than Fennec Pharmaceuticals. Sirona Biochem is trading at a lower price-to-earnings ratio than Fennec Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Fennec Pharmaceuticals beats Sirona Biochem on 4 of the 6 factors compared between the two stocks.

Sirona Biochem (CVE:SBM) and Antibe Therapeutics (TSE:ATE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Sirona Biochem and Antibe Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sirona BiochemN/AN/AN/A
Antibe TherapeuticsN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Sirona Biochem and Antibe Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sirona Biochem0000N/A
Antibe Therapeutics00203.00

Antibe Therapeutics has a consensus price target of C$7.75, suggesting a potential upside of 79.40%. Given Antibe Therapeutics' higher probable upside, analysts plainly believe Antibe Therapeutics is more favorable than Sirona Biochem.

Valuation and Earnings

This table compares Sirona Biochem and Antibe Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sirona BiochemC$123,870.00716.78C$-2,959,580.00C($0.01)-30.00
Antibe TherapeuticsC$9.33 million21.07C$-35,814,009.00C($0.79)-5.49

Sirona Biochem has higher earnings, but lower revenue than Antibe Therapeutics. Sirona Biochem is trading at a lower price-to-earnings ratio than Antibe Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Antibe Therapeutics beats Sirona Biochem on 4 of the 7 factors compared between the two stocks.

Sirona Biochem (CVE:SBM) and Oncolytics Biotech (TSE:ONC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Sirona Biochem and Oncolytics Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sirona BiochemN/AN/AN/A
Oncolytics BiotechN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Sirona Biochem and Oncolytics Biotech, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sirona Biochem0000N/A
Oncolytics Biotech01202.67

Oncolytics Biotech has a consensus price target of C$6.00, suggesting a potential upside of 64.38%. Given Oncolytics Biotech's higher probable upside, analysts plainly believe Oncolytics Biotech is more favorable than Sirona Biochem.

Valuation and Earnings

This table compares Sirona Biochem and Oncolytics Biotech's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sirona BiochemC$123,870.00716.78C$-2,959,580.00C($0.01)-30.00
Oncolytics BiotechN/AN/AN/AC($0.56)-6.52

Oncolytics Biotech has lower revenue, but higher earnings than Sirona Biochem. Sirona Biochem is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Summary

Oncolytics Biotech beats Sirona Biochem on 3 of the 5 factors compared between the two stocks.

Sirona Biochem (CVE:SBM) and ImmunoPrecise Antibodies (CVE:IPA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Sirona Biochem and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sirona BiochemN/AN/AN/A
ImmunoPrecise AntibodiesN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Sirona Biochem and ImmunoPrecise Antibodies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sirona Biochem0000N/A
ImmunoPrecise Antibodies0000N/A

Valuation and Earnings

This table compares Sirona Biochem and ImmunoPrecise Antibodies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sirona BiochemC$123,870.00716.78C$-2,959,580.00C($0.01)-30.00
ImmunoPrecise AntibodiesC$17.18 million13.08C$-4,082,906.00C($0.21)-55.05

Sirona Biochem has higher earnings, but lower revenue than ImmunoPrecise Antibodies. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Sirona Biochem, indicating that it is currently the more affordable of the two stocks.

Summary

Sirona Biochem beats ImmunoPrecise Antibodies on 4 of the 5 factors compared between the two stocks.


Sirona Biochem Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
IMV logo
IMV
IMV
1.2$3.40+1.8%C$226.16 millionC$3,000.00-5.88
RVX
Resverlogix
0.7$0.89+2.2%C$212.93 millionN/A63.57Upcoming Earnings
News Coverage
FRX
Fennec Pharmaceuticals
0.5$7.54+7.2%C$210.10 millionC$170,000.00-7.89
ATE
Antibe Therapeutics
1.3$4.32+5.1%C$206.60 millionC$9.33 million-5.49Gap Down
ONC
Oncolytics Biotech
1.2$3.65+0.8%C$191.02 millionN/A-6.52
IPA
ImmunoPrecise Antibodies
0.4$11.78+3.7%C$123.03 millionC$17.18 million-55.05
HBP
Helix BioPharma
0.5$0.88+3.4%C$119.96 millionN/A-16.00Gap Up
ACST
Acasti Pharma
0.8$0.54+1.9%C$88.79 millionC$81,000.0015.88News Coverage
NVH
Novoheart
0.5$0.53+1.9%C$79.23 millionC$423,500.00-13.95
MBX
Microbix Biosystems
0.9$0.59+3.4%C$66.76 millionC$11.64 million-11.57News Coverage
PDP
Pediapharm
0.5$0.30+1.7%C$66.36 millionC$11.16 million-4.11
PMN
ProMIS Neurosciences
0.5$0.19+2.7%C$55.07 millionC$1,787.00-9.25News Coverage
Gap Up
COV
Covalon Technologies
0.6$1.55+3.2%C$37.44 millionC$23.84 million-6.51Gap Down
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.25+2.0%C$34.02 millionC$13.02 million-0.36Gap Up
IGX
IntelGenx Technologies
0.9$0.55+1.8%C$30.87 millionC$1.54 million-6.79
QPT
Quest PharmaTech
0.8$0.11+13.6%C$21.76 millionC$38,871.000.17Gap Down
CZO
Ceapro
0.7$0.74+1.4%C$21.65 millionC$16.14 million22.42
CTX
Crescita Therapeutics
0.6$0.80+6.3%C$16.52 millionC$15.64 million400.00
KNE
Kane Biotech
0.4$0.19+0.0%C$14.12 millionC$1.34 million-5.43
GSD
Devonian Health Group
0.5$0.26+3.8%C$13.96 millionC$1.59 million-5.42High Trading Volume
PAS
Pascal Biosciences
0.6$0.08+6.3%C$12.70 millionN/A-3.64
NSP
Naturally Splendid Enterprises
0.6$0.06+0.0%C$11.06 millionC$2.03 million-1.40
MPH
Medicure
0.7$1.63+1.2%C$10.80 millionC$12.71 million-1.05Gap Up
BTI
Bioasis Technologies
0.7$0.34+1.5%C$10.16 millionC$4.12 million30.45Gap Down
HEM
Hemostemix
0.6$0.33+6.2%C$9.07 millionN/A-1.93Gap Down
ICO
iCo Therapeutics
0.5$0.11+0.0%C$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.38+2.6%C$6.94 millionC$5.60 million7.04
IOT
Innovotech
0.8$0.17+5.9%C$6.52 millionC$1.04 million85.00Gap Down
BCT
BriaCell Therapeutics
0.5$3.61+5.8%C$4.48 millionN/A-1.17
RVV
Revive Therapeutics
0.5$0.08+12.5%C$3.62 millionN/A-3.64High Trading Volume
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04+71.4%C$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03+16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01+0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.3$46.81+1.6%C$0.00C$267.59 million51.44
LTY
Liberty Biopharma
0.6$2.00+100.0%C$0.00N/A-12.66Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
SCYB
Scythian Biosciences
0.5$3.49+6.3%C$0.00N/A0.00High Trading Volume
ABCN
VIVO Cannabis
0.6$1.32+5.3%C$0.00N/A0.00News Coverage
Gap Down
VP
Vodis Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.